Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
Abstract Leiomyosarcoma (LMS) is a rare soft tissue sarcoma (STS) that begins in smooth muscle tissue and most often initiates in the abdomen or uterus. Compared with other uterine cancers, uterine LMS (ULMS) is an aggressive tumor with poor prognosis and a high risk of recurrence and death, regardl...
Main Authors: | Sonam Mittal, Ishaque Pulikkal Kadamberi, Hua Chang, Feng Wang, Sudhir Kumar, Shirng-Wern Tsaih, Christopher J. Walker, Pradeep Chaluvally-Raghavan, John Charlson, Yosef Landesman, Sunila Pradeep |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-09-01
|
Series: | Experimental Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40164-023-00443-w |
Similar Items
-
Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis
by: Xinyuan Gu, et al.
Published: (2023-12-01) -
Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors
by: Antonella Lucia Marretta, et al.
Published: (2021-09-01) -
E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1
by: Bert Kwanten, et al.
Published: (2023-04-01) -
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Cristina Gasparetto, et al.
Published: (2021-02-01) -
Therapeutic efficacy of a four-year treatment with eribulin in a patient with uterine leiomyosarcoma: A case report
by: Motoki Matsuura, et al.
Published: (2023-06-01)